Ligand Pharmaceuticals Inc (LGND)
70.37
-0.63
(-0.89%)
USD |
NASDAQ |
Apr 25, 16:00
70.26
-0.11
(-0.16%)
Pre-Market: 20:00
Ligand Pharmaceuticals Cash from Operations (TTM): 49.58M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 49.58M |
| September 30, 2023 | 94.98M |
| June 30, 2023 | 107.83M |
| March 31, 2023 | 119.79M |
| December 31, 2022 | 137.85M |
| September 30, 2022 | 112.02M |
| June 30, 2022 | 111.56M |
| March 31, 2022 | 120.06M |
| December 31, 2021 | 78.80M |
| September 30, 2021 | 51.69M |
| June 30, 2021 | 44.41M |
| March 31, 2021 | 48.42M |
| December 31, 2020 | 54.59M |
| September 30, 2020 | 46.71M |
| June 30, 2020 | 27.77M |
| March 31, 2020 | -57.67M |
| December 31, 2019 | -29.34M |
| September 30, 2019 | 10.58M |
| June 30, 2019 | 43.85M |
| March 31, 2019 | 178.56M |
| December 31, 2018 | 194.06M |
| September 30, 2018 | 192.80M |
| June 30, 2018 | 193.36M |
| March 31, 2018 | 130.11M |
| December 31, 2017 | 88.57M |
| Date | Value |
|---|---|
| September 30, 2017 | 75.98M |
| June 30, 2017 | 66.86M |
| March 31, 2017 | 66.84M |
| December 31, 2016 | 60.73M |
| September 30, 2016 | 55.67M |
| June 30, 2016 | 47.59M |
| March 31, 2016 | 47.26M |
| December 31, 2015 | 41.73M |
| September 30, 2015 | 38.31M |
| June 30, 2015 | 31.61M |
| March 31, 2015 | 25.57M |
| December 31, 2014 | 20.57M |
| September 30, 2014 | 22.35M |
| June 30, 2014 | 18.26M |
| March 31, 2014 | 21.19M |
| December 31, 2013 | 20.69M |
| September 30, 2013 | 10.83M |
| June 30, 2013 | 10.28M |
| March 31, 2013 | 2.608M |
| December 31, 2012 | 0.161M |
| September 30, 2012 | 5.006M |
| June 30, 2012 | 4.861M |
| March 31, 2012 | -2.452M |
| December 31, 2011 | -1.172M |
| September 30, 2011 | -9.489M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-57.67M
Minimum
Mar 2020
137.85M
Maximum
Dec 2022
61.76M
Average
51.69M
Median
Sep 2021
Cash from Operations (TTM) Benchmarks
| ANI Pharmaceuticals Inc | 118.96M |
| ADMA Biologics Inc | 8.80M |
| Viking Therapeutics Inc | -54.87M |
| Corcept Therapeutics Inc | 127.04M |
| Palatin Technologies Inc | -26.54M |